Curaleaf Takeover Bid for Aurora
Curaleaf takeover bid for Aurora offers 0.3463 shares plus US$0.75, implying US$4.00 per share and no financing condition, prompting trader scrutiny.
KEY TAKEAWAYS
- Curaleaf proposed 0.3463 shares plus US$0.75 cash, implying US$4.00 per Aurora share and capped at US$5.00.
- The proposal represented a 45% premium to a US$2.75 30-day VWAP and implied US$272 million valuation.
- Curaleaf said the offer contained no due-diligence or financing conditions and no formal bid had been commenced.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Curaleaf said in a press release on Aug. 11, 2026, that it intends to launch a takeover bid for Aurora Cannabis, proposing a stock-and-cash offer it described as margin-accretive and aimed at expanding the companies’ international footprint.
Offer Terms and Strategic Rationale
Curaleaf Holdings, Inc. (TSX: CURA; OTCQX: CURLF) proposed exchanging 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash per Aurora Cannabis Inc. (NASDAQ: ACB; TSX: ACB) share. The company said this mix implies US$4.00 per Aurora share, capped at US$5.00 if Curaleaf’s stock rises materially, with the stock component adjusted accordingly. The proposal represents a 45% premium to Aurora’s 30-day volume-weighted average price of US$2.75 and a 110% premium excluding Aurora’s balance-sheet cash. Curaleaf said the offer would contain no due-diligence or financing conditions. Secondary reporting valued the proposal at approximately US$272 million.
Curaleaf said the bid aims to combine Aurora’s EU-GMP cultivation, manufacturing, and medical cannabis operations with Curaleaf’s distribution platform and international reach. The goal is to improve margins and patient access across Europe, Canada, Australia, and New Zealand. The company expects at least US$40 million in annual cost synergies and said the combined entity would operate in 17 countries with trailing 12-month revenue exceeding US$1.5 billion.
Curaleaf said it made multiple private approaches before going public with the proposal. The company framed the release around deal rationale without providing updated operating guidance. Secondary reports indicated that formal offer documents would be filed with Canadian securities regulators and the U.S. Securities and Exchange Commission when the bid is formally launched.
The company noted, “No formal take-over bid has been commenced and there is no assurance the proposed offer will ultimately be made.” Secondary reporting said the formal offer would remain open for 105 days with extension rights. Curaleaf reserved the right to abandon the bid if Aurora adopts a rights plan, disposes of major assets, issues significant shares, makes a major acquisition, or enters a competing transaction. The materials reviewed did not identify any target-board approval, merger agreement, or regulatory approvals.
